Low Testosterone Symptoms: Labs, Diagnosis, and Next Steps

Recognizing the Symptoms of Low Testosterone

The clinical picture of low testosterone extends well beyond a single complaint. Men with hypogonadism typically present with a constellation of sexual, physical, and psychological symptoms that develop gradually over months or years, making them easy to dismiss as "just aging" [1].

Sexual symptoms tend to appear first. Reduced libido, fewer spontaneous erections, and erectile dysfunction are the most specific clinical markers of testosterone deficiency, according to the Endocrine Society's 2018 Clinical Practice Guideline [1]. A population-based analysis in the European Male Ageing Study (EMAS, N=3,369) found that only three symptoms were syndromically associated with low testosterone: decreased frequency of morning erections, decreased frequency of sexual thoughts, and erectile dysfunction [2]. These three sexual symptoms, combined with a total testosterone below 320 ng/dL, had the highest diagnostic specificity.

Physical changes accumulate over longer timelines. Loss of lean muscle mass, increased body fat (particularly visceral adiposity), reduced bone mineral density, and decreased body hair are well-documented consequences of prolonged testosterone deficiency [3]. The Testosterone Trials (TTrials, N=790) demonstrated that men aged 65 and older with testosterone levels below 275 ng/dL had measurably lower bone density at the spine and hip compared to age-matched controls with normal levels [4].

Mood and cognitive symptoms round out the picture. Fatigue that persists despite adequate sleep, depressed mood, irritability, difficulty concentrating, and reduced motivation are commonly reported [1]. These overlap heavily with depression, thyroid disease, and sleep disorders, which is precisely why lab confirmation is required before attributing them to testosterone.

Not every man with low T will notice every symptom. Some report only fatigue and brain fog. Others notice libido changes but feel physically fine. The variability is real.

What Counts as "Low" Testosterone?

The Endocrine Society defines male hypogonadism as a total testosterone concentration below 300 ng/dL (10.4 nmol/L) measured on at least two separate morning blood draws [1]. This threshold is not arbitrary. It represents approximately the lower 2.5th percentile of healthy young men aged 19 to 39 in the Harmonized Normative Dataset.

Timing of the draw matters substantially. Testosterone follows a circadian rhythm, peaking between 7:00 and 10:00 AM and declining 20% to 35% by late afternoon [5]. A sample drawn at 3:00 PM may read 250 ng/dL in a man whose morning value is 340 ng/dL. The guideline is explicit: "measure total testosterone in the morning, preferably between 0700 and 1000 hours" [1]. Fasting is preferred because glucose ingestion can transiently suppress testosterone by up to 25%, as shown in a study of 74 men with normal glucose tolerance published in Clinical Endocrinology [6].

Free testosterone becomes important when total testosterone falls in the borderline range of 200 to 400 ng/dL, or when conditions that alter sex hormone-binding globulin (SHBG) are present. Obesity lowers SHBG, making total testosterone appear lower while free testosterone may remain adequate. Aging and liver disease raise SHBG, potentially masking true deficiency. Calculated free testosterone (using the Vermeulen equation) below 6.5 ng/dL supports the diagnosis [1].

A single low reading is not diagnostic. Acute illness, opioid use, high-dose corticosteroids, poor sleep, and extreme caloric restriction can all transiently suppress testosterone [7]. Two confirmed low values are the minimum.

The Full Lab Panel: What to Order and Why

A total testosterone level is the starting point, but a complete diagnostic workup requires several additional tests to distinguish primary from secondary hypogonadism and to rule out mimics [1].

Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) separate the two major categories. Elevated LH and FSH with low testosterone indicates primary hypogonadism, meaning the testes are failing despite adequate pituitary signaling. Common causes include Klinefelter syndrome, prior orchitis, chemotherapy, and aging-related testicular decline [8]. Low or inappropriately normal LH with low testosterone points to secondary (central) hypogonadism, suggesting the hypothalamus or pituitary is not sending adequate signals. Pituitary tumors, hyperprolactinemia, obesity, opioid use, and obstructive sleep apnea are frequent culprits [1].

Prolactin should be measured in all cases of secondary hypogonadism. Elevated prolactin may indicate a prolactinoma, which requires its own targeted treatment rather than testosterone replacement [9].

Complete blood count (CBC) serves dual purposes. Anemia is a consequence of chronic testosterone deficiency, and a pre-treatment hematocrit establishes a baseline before starting TRT, which stimulates erythropoiesis and can push hematocrit above 54% [1].

Metabolic panel, fasting glucose, and HbA1c screen for type 2 diabetes and metabolic syndrome. The relationship between low testosterone and insulin resistance is bidirectional. In the T4DM trial (N=1,007), testosterone treatment in men with prediabetes or newly diagnosed type 2 diabetes reduced the proportion who met criteria for diabetes at 2 years by 40% relative to placebo (12% vs. 21%, P<0.001) [10].

Thyroid-stimulating hormone (TSH) and iron studies (ferritin, transferrin saturation) help exclude hypothyroidism and hemochromatosis, both of which can cause fatigue and hypogonadism simultaneously [1].

SHBG refines interpretation when total testosterone is borderline. A calculated free testosterone or bioavailable testosterone clarifies whether the man is truly deficient or whether binding-protein shifts explain the number.

Semen analysis is indicated if the patient has current or future fertility goals. This is a step many clinicians forget to discuss before initiating TRT, which reliably suppresses sperm production within 3 to 6 months [11].

Why Testosterone Drops: Common and Overlooked Causes

Age alone accounts for a steady decline. The Baltimore Longitudinal Study of Aging documented an average decrease of 1.6% per year in total testosterone and 2% to 3% per year in free testosterone after age 30 [12]. But age-related decline alone does not explain all cases. True pathological hypogonadism has identifiable drivers.

Obesity is the most common modifiable cause. Adipose tissue expresses aromatase, which converts testosterone to estradiol. The EMAS study found that a BMI increase of 5 kg/m² produced a testosterone decrease comparable to 10 years of aging [2]. Weight loss can partially reverse this. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks vs. 2.4% with placebo [13]. While STEP-1 did not report testosterone as a primary endpoint, a sub-analysis of similar GLP-1 receptor agonist trials demonstrated testosterone increases of 100 to 200 ng/dL in obese men who lost more than 10% body weight [14].

Opioid-induced androgen deficiency affects up to 90% of men on chronic opioid therapy [15]. The hypothalamic-pituitary-gonadal axis is suppressed dose-dependently, and recovery after opioid cessation may take months.

Obstructive sleep apnea fragments sleep architecture and blunts the nocturnal LH pulse that drives testosterone synthesis [16]. Treating OSA with CPAP has shown mixed results for testosterone recovery in trials, but some men see partial improvement.

Other causes include pituitary adenomas, anabolic steroid use (which suppresses endogenous production, sometimes permanently), hemochromatosis (iron overload damages gonadotrophs), chronic kidney disease, HIV, and medications including ketoconazole, spironolactone, and certain anticonvulsants [1][7].

Diagnosis: Putting It All Together

"The diagnosis of hypogonadism requires both consistent symptoms and unequivocally low serum testosterone concentrations," states the Endocrine Society guideline [1]. Neither symptoms alone nor a single lab value is sufficient.

A practical diagnostic sequence looks like this. First visit: detailed symptom history, physical examination (including testicular volume assessment), and morning fasting total testosterone. If total testosterone is below 300 ng/dL, schedule a second confirmatory draw on a different day along with free testosterone, LH, FSH, prolactin, CBC, metabolic panel, TSH, and SHBG. If secondary hypogonadism is identified, pituitary MRI should be considered, particularly when LH is low and prolactin is elevated or testosterone is below 150 ng/dL [1].

The American Urological Association (AUA) 2018 guideline adds an important nuance: "Testosterone therapy should only be offered to patients with low testosterone and associated symptoms, after a thorough discussion of the potential benefits, risks, and alternatives" [17]. The AUA also recommends against screening asymptomatic men.

Dr. Shalender Bhasin, lead author of the Endocrine Society guideline and professor at Harvard Medical School, has noted: "Testosterone should not be prescribed based on age-related symptoms alone without biochemical confirmation, as many of these symptoms are nonspecific and overlap with other medical conditions" [1].

Treatment Options After Confirmed Diagnosis

Once hypogonadism is confirmed and reversible causes are addressed (weight loss for obesity, CPAP for OSA, opioid taper when possible), testosterone replacement therapy becomes the primary intervention for symptomatic men who are not trying to conceive [1].

TRT formulations include intramuscular injections (testosterone cypionate or enanthate, typically 100 to 200 mg every 1 to 2 weeks), transdermal gels (1% or 1.62% applied daily), transdermal patches, nasal testosterone (Natesto), subcutaneous pellets (Testopel), and oral testosterone undecanoate (Jatenzo) [17]. Each route has trade-offs in convenience, cost, testosterone stability, and side-effect profile.

The TTrials provided the most comprehensive efficacy data for older men. Across seven coordinated trials in 790 men aged 65 and older with testosterone below 275 ng/dL, one year of transdermal testosterone gel improved sexual function, walking distance, mood, and bone mineral density compared to placebo [4]. The sexual function benefit was the most pronounced, with a mean improvement of 0.58 standard deviations on the Derogatis Interview for Sexual Functioning.

For men who want to preserve fertility, clomiphene citrate (25 to 50 mg every other day, off-label) or human chorionic gonadotropin (hCG, 1,500 to 3 to 000 IU two to three times per week) can raise endogenous testosterone without suppressing spermatogenesis [18]. Clomiphene blocks estrogen feedback at the hypothalamus, stimulating LH release. In a retrospective series of 86 men, clomiphene raised mean testosterone from 228 ng/dL to 612 ng/dL while maintaining sperm counts [18].

Enclomiphene, the trans-isomer of clomiphene, received FDA approval in 2023 and offers a cleaner pharmacologic profile with less estrogenic activity.

Monitoring on Therapy: What Labs to Repeat and When

Starting TRT is not the finish line. Ongoing monitoring protects against complications and ensures the dose is achieving the target range of 400 to 700 ng/dL at trough [1].

The Endocrine Society recommends checking testosterone, hematocrit, and PSA at 3 to 6 months after initiation, then at 12 months, and annually thereafter [1]. Hematocrit above 54% requires dose reduction, phlebotomy, or switching to a shorter-acting formulation. PSA monitoring is not because testosterone causes prostate cancer (the TRAVERSE trial, N=5,204, showed no increased prostate cancer incidence with TRT over a median 33 months [19]), but because undiagnosed prostate cancer is a contraindication to therapy.

Bone density should be reassessed at 1 to 2 years in men who had osteopenia or osteoporosis at baseline [1]. Lipid panels deserve periodic checks, as testosterone can lower HDL modestly. Mood and sexual function questionnaires at each visit help document ongoing benefit.

The TRAVERSE cardiovascular safety trial, published in the New England Journal of Medicine, followed 5,204 men aged 45 to 80 with hypogonadism and cardiovascular risk factors. TRT did not increase the incidence of major adverse cardiovascular events (7.0% TRT vs. 7.3% placebo, hazard ratio 0.96 to 95% CI 0.78 to 1.17) [19]. This resolved a decade of uncertainty following the 2010 TOM trial and 2013 VA observational study that had raised cardiovascular concerns.

When to See a Specialist

Primary care clinicians can diagnose and manage straightforward cases of hypogonadism. Referral to an endocrinologist or urologist is appropriate when the cause is unclear, secondary hypogonadism is suspected (potential pituitary pathology), the patient is under 30, fertility preservation is a priority, or initial treatment fails to improve symptoms despite adequate testosterone levels [1][17].

Men under 40 with confirmed low testosterone deserve a particularly thorough workup. Hypogonadism in this age group is less likely to be purely functional and more likely to reflect genetic conditions (Klinefelter syndrome affects 1 in 660 men), pituitary disease, or prior anabolic steroid use [8].

Klinefelter syndrome (47,XXY) is the most common genetic cause of primary hypogonadism and is underdiagnosed. Approximately 75% of affected men are never identified [8]. A karyotype should be ordered in any young man with small, firm testes (volume <6 mL), gynecomastia, and primary hypogonadism. The average age at diagnosis in Klinefelter syndrome is 27 years, according to data from the National Institutes of Health [20].

The initial lab draw costs between $50 and $200 depending on insurance coverage and the panel ordered. Most insurance plans cover testosterone testing when clinical symptoms are documented. TRT costs range from $30 to $50 per month for generic testosterone cypionate injections to $400 or more for branded gels and oral formulations.